ISPOR - Economic Impact of The Addition of Axitinib as a Second Line Treatment for Metastatic Renal cell Carcinoma in the Ecuatorian Public Heathcare Sector

Full Text

Economic Impact of The Addition of Axitinib as a Second Line Treatment for Metastatic Renal cell Carcinoma in the Ecuatorian Public Heathcare Sector

Abstract

Authors

A. Rosado-Buzzo M. Albuja L. Garcia-Molliendo G. Luna-Casas

Back to Volume 18, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now